Transcat (NASDAQ:TRNS) Rating Reiterated by Oppenheimer

Transcat (NASDAQ:TRNS)‘s stock had its “outperform” rating reissued by research analysts at Oppenheimer in a research note issued on Thursday, Benzinga reports. They presently have a $125.00 price objective on the scientific and technical instruments company’s stock, up from their previous price objective of $120.00. Oppenheimer’s price target would suggest a potential upside of 15.70% from the company’s previous close.

Several other research analysts have also recently commented on the stock. TheStreet raised shares of Transcat from a “c+” rating to a “b” rating in a report on Wednesday, January 31st. HC Wainwright reaffirmed a “buy” rating and set a $124.00 target price on shares of Transcat in a report on Tuesday.

Transcat Stock Up 2.7 %

Transcat stock opened at $108.04 on Thursday. The stock has a market cap of $953.89 million, a P/E ratio of 83.11 and a beta of 0.59. The company has a quick ratio of 2.81, a current ratio of 3.37 and a debt-to-equity ratio of 0.01. Transcat has a twelve month low of $74.89 and a twelve month high of $115.41. The company’s 50-day moving average price is $108.50 and its two-hundred day moving average price is $102.00.

Transcat (NASDAQ:TRNS) last announced its earnings results on Monday, January 29th. The scientific and technical instruments company reported $0.38 EPS for the quarter, topping the consensus estimate of $0.35 by $0.03. Transcat had a net margin of 4.16% and a return on equity of 9.32%. The company had revenue of $65.17 million for the quarter, compared to analysts’ expectations of $63.36 million. As a group, analysts expect that Transcat will post 1.33 EPS for the current year.

Insider Buying and Selling at Transcat

In other Transcat news, CEO Lee D. Rudow sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $111.30, for a total value of $556,500.00. Following the sale, the chief executive officer now owns 108,478 shares in the company, valued at $12,073,601.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Charles P. Hadeed sold 700 shares of Transcat stock in a transaction on Monday, February 12th. The shares were sold at an average price of $113.00, for a total transaction of $79,100.00. Following the transaction, the director now owns 22,678 shares in the company, valued at $2,562,614. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Lee D. Rudow sold 5,000 shares of Transcat stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $111.30, for a total transaction of $556,500.00. Following the transaction, the chief executive officer now owns 108,478 shares in the company, valued at approximately $12,073,601.40. The disclosure for this sale can be found here. Insiders have sold 8,073 shares of company stock worth $900,023 over the last quarter. Corporate insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Transcat

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Transcat by 13.3% during the third quarter. Vanguard Group Inc. now owns 425,378 shares of the scientific and technical instruments company’s stock worth $41,674,000 after purchasing an additional 49,828 shares during the period. Monashee Investment Management LLC acquired a new position in shares of Transcat during the third quarter worth $588,000. Quadrature Capital Ltd acquired a new position in shares of Transcat during the third quarter worth $2,847,000. Rice Hall James & Associates LLC raised its stake in Transcat by 59.2% during the third quarter. Rice Hall James & Associates LLC now owns 28,781 shares of the scientific and technical instruments company’s stock worth $2,820,000 after buying an additional 10,697 shares during the last quarter. Finally, Conestoga Capital Advisors LLC raised its stake in Transcat by 0.6% during the fourth quarter. Conestoga Capital Advisors LLC now owns 762,861 shares of the scientific and technical instruments company’s stock worth $83,404,000 after buying an additional 4,805 shares during the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.